What is it?
What Triacetyluridine is
3Triacetyluridine (TAU) and uridine triacetate are names for the same acetylated uridine prodrug. Uridine and uridine-containing nucleotides occur in normal metabolism and foods, but TAU is not the naturally occurring dietary form. TAU is also not uridine monophosphate (UMP), and finished supplements are not interchangeable with prescription VISTOGARD or XURIDEN.
Names, aliases and forms
Mechanisms of action
Acetylation improves uridine delivery
1Uridine triacetate is deacetylated by esterases to yield circulating uridine. Uridine participates in pyrimidine and RNA metabolism, while prescription rescue relies on uridine triphosphate competing with a toxic fluorouracil metabolite for RNA incorporation. This mechanism does not prove broad cognitive enhancement.
Potential effects and evidence map
Human pharmacokinetic studies support the central identity claim: oral uridine triacetate raises circulating uridine more efficiently than equimolar uridine. That is bioavailability evidence, not cognitive efficacy. The main human mood study enrolled 11 people with bipolar depression, used doses up to 18 g/day over 6 weeks, and was open-label without a placebo group. Memory and neuroprotection findings come mainly from mouse disease models. There is therefore no reliable basis for healthy-user memory, focus, motivation, or anti-ageing claims, and prescription rescue or rare-disease evidence should not be repurposed as nootropic proof.
One 11-person open-label bipolar-depression study reported symptom changes over six weeks; it does not establish a general mood benefit or treatment effect.
Memory findings are from mouse disease models, not controlled human cognitive trials or healthy-user studies.
Uridine and pyrimidine biology provide a plausible cellular mechanism, but human long-term brain-health outcomes are not established.
No reliable human evidence establishes improved focus, attention, or concentration in healthy users.
Triacetyluridine is not an established stimulant, wakefulness aid, or productivity compound.
Typical dosages and timing
The bipolar pilot used doses up to 18 g/day. U.S. prescription labels use entirely different regimens for emergency fluoropyrimidine rescue and hereditary orotic aciduria. No consumer "typical dose" is displayed because these contexts do not validate a nootropic dosing range.
Timing & effect horizon
The current VISTOGARD label reports peak plasma uridine after about 2-3 hours and a uridine The time for blood levels to fall by half during the final elimination phase.Source of about 2-2.5 hours. A TAU-rich nutritional formulation peaked somewhat earlier in a separate study. Formulation and dose matter.
Plasma timing confirms absorption; it does not establish when focus, memory, mood, or energy effects begin or how long they last. The only human mood pilot assessed change over six weeks, not as a same-day nootropic effect.
Safety, side effects and risk profile
Outside clinician-directed emergency rescue, uridine triacetate may diminish fluorouracil or capecitabine efficacy; people receiving fluoropyrimidine therapy should not self-use TAU.
Vomiting, nausea, and diarrhoea occurred in VISTOGARD trials at large prescription rescue doses.
U.S. prescription approvals for VISTOGARD and XURIDEN are narrow and do not approve nootropic, mood, memory, anti-ageing, or general wellness claims.
Human pregnancy and lactation information is insufficient for wellness use; prescription emergency or rare-disease decisions have a different benefit-risk context.
TAU, uridine, UMP, nucleotide blends, prescription granules, and finished supplements differ in formulation, exposure, indication, and evidence.
Current VISTOGARD and XURIDEN labels list no general contraindications or warnings, and serious general toxicity is not prominent. Low overall risk reflects that baseline while keeping a severe population-specific exception highly visible: people receiving fluorouracil or capecitabine should not self-use TAU outside clinician-directed emergency rescue.
In 135 VISTOGARD-treated patients, vomiting occurred in 10%, nausea in 5%, and diarrhoea in 3%. These emergency high-dose data cannot be translated directly to lower-dose supplements, but they identify the clearest known tolerability pattern.
VISTOGARD has only limited pregnancy case reports, and XURIDEN reports no available pregnancy data. Prescription rescue and rare-disease treatment may justify use under specialist care, but these labels do not establish routine wellness safety.
Interactions and cautions
The label reports no meaningful CYP inhibition or induction in vitro. Uridine triacetate inhibited a P-glycoprotein substrate in vitro, however, so interactions with oral P-glycoprotein-substrate medicines cannot be excluded; human in-vivo data are unavailable.
Legal and regulatory status
VISTOGARD is FDA-approved for emergency fluorouracil/capecitabine overdose or early severe toxicity, and XURIDEN for hereditary orotic aciduria. Neither approval covers memory, focus, bipolar disorder, depression, anti-ageing, or general wellness. Other-country status must be checked locally.
For January-March 2026, FDA listed device occlusion as a potential signal for VISTOGARD and XURIDEN and said it is evaluating whether regulatory action is needed. This is not proof that uridine triacetate causes systemic toxicity and is not, by itself, a label change.
Practical buying and quality notes
- Check the actual ingredient rather than relying on "uridine" marketing. Triacetyluridine/uridine triacetate, uridine, UMP, RNA or nucleotide blends, VISTOGARD and XURIDEN differ in molecule, formulation, dose, evidence, and legal context.3
- For finished supplements, compare the stated TAU amount, full ingredient list, capsule count, batch testing, manufacturer transparency, storage, and jurisdiction-specific sale status. A prescription-drug citation does not validate a supplement's identity or claims.3
- The only human mood signal comes from a very small bipolar-depression pilot. People with bipolar disorder, mania or hypomania history, unstable mood, or psychiatric treatment should not turn that study into a self-experiment.5
FAQ
Is Triacetyluridine a proven nootropic?
6No. Human research supports oral uridine delivery, while mood evidence is an uncontrolled 11-person pilot and memory evidence is mainly from animal disease models. Healthy-user cognitive efficacy is not established.
Does Triacetyluridine have an acute effect?
1Plasma uridine peaks within a few hours, but no reliable study establishes a same-day focus, memory, energy, or mood effect or a cognitive-effect duration. Pharmacokinetics should not be presented as subjective-effect timing.
Why is the overall risk low?
1For people outside fluoropyrimidine treatment, current labels do not show a broad serious-toxicity pattern. The major exception remains critical: outside emergency rescue, uridine triacetate may reduce fluorouracil or capecitabine efficacy, so that interaction stays rated 5/5.
References
- DailyMed. VISTOGARD (uridine triacetate) oral granules prescribing information. Revised 2023-10; accessed 2026-07-14.
- DailyMed. XURIDEN (uridine triacetate) oral granules prescribing information. Updated 2025-02-18; accessed 2026-07-14.
- PubChem. Uridine triacetate (CID 20058). Accessed 2026-07-14.
- FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Early-Onset Severe Toxicities. Clinical Cancer Research. 2016;22(18):4545-4549.
- Jensen JE, et al. Triacetyluridine decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol. 2008;16(3):199-206.
- Weinberg ME, et al. Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement. PLoS One. 2011;6(2):e14709.
- Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease. 2006;24(3):455-465.
- Uridine prodrug improves memory in Tg2576 and TAPP mice and reduces pathological factors associated with Alzheimer's disease in related models. Journal of Alzheimer's Disease. 2013;36(4):679-695.
- U.S. Food and Drug Administration. January-March 2026 potential signals of serious risks identified by the FDA Adverse Event Monitoring System. Content current 2026-06-30.